As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.
After being ousted from the top spot last year, Roche has clawed its way back to dominance among rare disease patient groups’ assessments of drugmaker reputations.
THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population.
Amgen`s Biologic Repatha (Evolocumab) Receives Suppl Approvals in US
Amgen`s Biologic Amjevita (Adalimumab) Receives Suppl Approvals in US
LARGO, Maryland/WASHINGTON, Aug 15 (Reuters) - The United States has negotiated down the prices of 10 top-selling prescription drugs used by Medicare by as much as 79%, hoping to save $6 billion in the first year as part of a plan hailed on Thursday by President Joe Biden with the aim to ease anger about high prices ahead of November elections.
Amgen sues Samsung biotech unit over bone drug copies
When the FDA approved Amgen’s Imdelltra in May, the T-cell engager was hailed as a breakthrough for the treatment of small cell lung cancer (SCLC) and as the first DLL3-targeting therapy of potentially many more to come. But, in granting the accelerated approval, the FDA had to work through a “large number” of underreported adverse events and several protocol deviations from a pivotal trial.
With a quarter of the world’s population expected to have obesity by 2035 and the market for obesity therapeutics predicted to hit $131 billion within the next five years, it’s no wonder the disease is one of biopharma’s hottest targets. While the space is currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, several other candidates are making their way through the pipeline, their makers aiming to snag a piece of the lucrative pie.
US biotech giant Amgen announced plans to open a new technology and innovation site in Hyderabad, India. The site will be located in HITEC City and will occupy six floors of the RMZ Spire Tower. It is expected to be operational in Q4 2024 and has the potential to accommodate up to 3,000 people.